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Following a screen for neuromuscular mouse mutants, we identified ostes, a novel N-ethyl N-nitrosourea-
induced mouse mutant with muscle atrophy. Genetic and biochemical evidence shows that upregulation
of the novel, uncharacterized transient receptor potential polycystic (TRPP) channel PKD1L2 (polycystic
kidney disease gene 1-like 2) underlies this disease. Ostes mice suffer from chronic neuromuscular impair-
ments including neuromuscular junction degeneration, polyneuronal innervation and myopathy. Ectopic
expression of PKD1L2 in transgenic mice reproduced the ostes myopathic changes and, indeed, caused
severe muscle atrophy in Tg(Pkd1l2)/Tg(Pkd1l2) mice. Moreover, double-heterozygous mice (ostes/1,
Tg(Pkd1l2)/0) suffer from myopathic changes more profound than each heterozygote, indicating positive cor-
relation between PKD1L2 levels and disease severity. We show that, in vivo, PKD1L2 primarily associates
with endogenous fatty acid synthase in normal skeletal muscle, and these proteins co-localize to costameric
regions of the muscle fibre. In diseased ostes/ostes muscle, both proteins are upregulated, and ostes/ostes
mice show signs of abnormal lipid metabolism. This work shows the first role for a TRPP channel in neuro-
muscular integrity and disease.
INTRODUCTION
Discovering the molecular mechanisms underlying neuromus-
cular degenerative diseases is pivotal to the development of
therapies for such heterogenous disorders. Model organisms
have assisted in the identification of novel neuromuscular
disease genes and genetic pathways (reviewed in 1–3). We
have exploited mouse mutagenesis to identify new neuromus-
cular mutants. In phenotype-driven screens of mutagenized
mice, simple measures of muscle strength such as wheel
running or grip strength have failed to consistently identify
mutants that show muscular defects at the histological level.
In addition, measuring progressive motor neuron loss in
mutagenized animals is not a suitable protocol for large-scale
screening programmes. In contrast, overt phenotypes such as
muscle atrophy, tremors, gait defects and growth retardation
have been used to signpost abnormal neuromuscular function
in mice (4,5). Using this simple paradigm, we identified
ostes in an N-ethyl N-nitrosourea (ENU) screen (6). The aim
of this work was to characterize this novel neuromuscular phe-
notype in the mouse and to provide insights into the under-
lying molecular mechanism. We present evidence that the
product of the genetically linked Pkd1l2 (polycystic kidney
disease gene 1-like 2) gene is grossly overexpressed in
ostes/ostes mice, and that ectopic expression of PKD1L2 in
transgenic mice leads to similar neuromuscular features. To
date, no analysis of PKD1L2 protein expression, localization
To whom correspondence should be addressed. Tel: þ44 1235841072; Fax: þ44 1235841000; Email: g.blanco@har.mrc.ac.uk
# 2009 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Human Molecular Genetics, 2009, Vol. 18, No. 19 3553–3566
doi:10.1093/hmg/ddp304
Advance Access published on August 4, 2009







or in vivo function has been done. Here, we show that
PKD1L2 is the first transient receptor potential polycystic
(TRPP) channel to be associated with neuromuscular function
and disease. Additionally, we show that abnormal lipid metab-
olism in PKD1L2-dysregulated mice is a key feature of this
disease.
RESULTS
Ostes mice show a complex neuromuscular phenotype
We assessed the neuromuscular system in ostes/ostes mice at
three levels of analysis. Grossly, ostes/ostes mice become
recognizable by their small size and reduced weight between
3 and 5 weeks of age (Fig. 1A) and remain small and light
throughout life (see weights of 12-week-old mice, Fig. 1B).
Ostes/ostes mice also show a moderate tremor of the hind
limbs upon suspension by the tail and have a poor reaching
response. Conversely, ostes/þ mice do not display any overt
abnormal phenotype. Sections of 24 ostes/ostes tissues includ-
ing heart did not reveal any pathology except for muscle at this
level of examination (data not shown). Haematoxylin and
eosin (H&E)-stained sections of hind limb muscles from
ostes/ostes mice show striking fibre size asymmetry, including
large compensatory fibres with internal nuclei (representative
pictures and quantifications in Fig. 1C, D and E). In addition,
clusters of fibres with pyknotic nuclei and scattered, small cen-
trally nucleated fibres are present, indicating fibre atrophy and
some regeneration, respectively (Fig. 1C and Supplementary
Material, Fig. S1). There is no evidence of macrophage infiltra-
tion (Supplementary Material, Fig. S2). Additionally, ostes/
ostes mice show widespread muscle atrophy, as indicated by
the average cross-sectional area of the muscle fibres (Fig. 1D
and E) and reflected in the overall muscle group size (see
insets in Fig. 1C). Despite the lack of gross phenotype in
ostes/þ mice, similar pathological hallmarks are evident in
ostes/þ hind limb muscle, but the pathology is milder and
there is no evidence of muscle atrophy (Fig. 1I and Supplemen-
tary Material, Fig. S3), indicating a semi-dominant action of the
ostes mutation in muscle.
Pyknotic nuclear clumps have been associated with dener-
vation of muscle fibres in amyotrophic lateral sclerosis and
bulbospinal muscular atrophy. Therefore, endplates, axons
and presynaptic axon terminals in lumbrical muscle whole-
mounts from 45-day-old ostes/ostes, ostes/þ and wild-type
mice were immunostained and examined for signs of denerva-
tion. Confocal microscopy revealed many denervated end-
plates in ostes/ostes muscles, characteristically showing a
plaque-like morphology, with or without contact to a visible
degenerating nerve terminal, or only partially occupied by a
small number of nerve terminal boutons (Fig. 1F). Addition-
ally, 40% of ostes/ostes motor endplates were polyneuron-
ally innervated by collateral branches of two or three axons.
All endplates in wild-type littermates had only one axon term-
inal per endplate. We assessed the function of polyinnervated
junctions in ostes mice by intracellular recordings of
nerve-evoked endplate potentials (EPPs) in extensor digitorum
longus (EDL) and soleus muscle from ostes/ostes (n ¼ 3)
mice. Recordings from ostes/ostes muscle in response to
graded stimulation of the nerve supply resolved two com-
ponents to the EPP with distinct thresholds in 20–30% of
muscle fibres (n ¼ 15–18 fibres per muscle), indicating func-
tional polyneuronal innervation (Fig. 1G). These recordings
corroborated the morphological evidence of enduring poly-
neuronal innervation in ostes/ostes mice. Fibre type distri-
bution in the soleus muscle region did not show any
differences between ostes/ostes and wild-type staining. Fibre
size asymmetry did not correlate with specific fibre type,
and there was no evidence of fibre type grouping (Fig. 1I
and Supplementary Material, Fig. S4).
Figure 1. Neuromuscular phenotypes of ostes and Tg(Pkd1l2) mice. (A) Photograph of representative 5-week-old wild-type (þ/þ) and ostes/ostes mice. Ostes/
ostes mice are small and weigh less than wild-type mice from 3–5 weeks of age. (B) Weight of 12-week-old wild-type (þ/þ) and ostes/ostes mice. Both male
and female ostes/ostes mice weigh significantly less than wild-type mice at 12 weeks of age (females: P ¼ 5.873E2 16, n ¼ 9 ostes/ostes, 22 wild-type; males:
P ¼ 1.143E2 12, n ¼ 11 ostes/ostes, 22 wild-type). Data are represented as mean+SEM. (C) Representative sections of gastrocnemius skeletal muscle from
45-day-old wild-type (þ/þ), ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2) mice, stained with H&E. Evidence of degenerative changes are present in ostes/ostes
muscle, including muscle atrophy, small fibres, striking fibre size asymmetry, pyknotic nuclei and centrally nucleated fibres (arrows). Muscles from
45-day-old Tg(Pkd1l2)/Tg(Pkd1l2) mice show similar pathological hallmarks. Scale bar: 20 magnification, 100 mm, 40, 50 mm. Inset: H&E-stained levelled
cross-sections of whole hind limbs from the same mice show the reduced size and muscle atrophy in ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2) hind limbs.
(D) Mean fibre size according to fibre type in soleus muscle from wild-type (þ/þ), ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2) mice. Mean fibre size in both
ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2) skeletal muscle is reduced compared with wild-type. Type-2 fibres show a small but significant reduction in size in
ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2) muscle. Fibre size was analysed in MYH7-stained sections (slow twitch) of soleus muscle from three 45-day-old
mice containing at least 80 fibres each. Data are represented as mean+SEM. (E) Fibre size distribution in 45-day-old wild-type (þ/þ), ostes/ostes and
Tg(Pkd1l2)/Tg(Pkd1l2) skeletal muscle. Fibre size was analysed in five H&E-stained sections of gastrocnemius from 45-day-old mice containing at least 80
fibres each. (F) Immunofluorescence photographs of NMJs in wholemount lumbrical muscle from wild-type (þ/þ) and ostes/ostes mice. Acetylcholine receptors
are labelled in red, and presynaptic boutons and axons in green. Wild-type (þ/þ) endplates are mononeuronally innervated, with one axon leading to each
endplate. Ostes/ostes endplates show both normal mononeuronal innervation (m), alongside abnormal polyneuronal innervation (p) where two or more axon
terminals innervate one endplate, in both 45-day-old and 9-month-old mice. In addition, some ostes/ostes endplates are denervated (d), characterized by a plaque-
like morphology of acetylcholine receptor staining and only partial or absent occupation by axon terminals. Scale bar, 20 mm. (G) Example of an intracellular
recording of nerve-evoked EPPs from an ostes/ostes EDL muscle, showing functional polyneuronal innervation. (H) Immunofluorescence photographs of NMJs
in wholemount hind limb muscle from 26-day-old Tg(Pkd1l2)/Tg(Pkd1l2) mice. Examples of an abnormal polyneuronal innervation (p) and a plaque-like par-
tially denervated endplate (d) are shown. (I) Fibre type analysis of levelled cross-sections of 45-day-old þ/þ, ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2) hind limb
skeletal muscle. There is no evidence of fibre type grouping, and fibre size asymmetry does not correlate with specific fibre type in either ostes/ostes or
Tg(Pkd1l2)/Tg(Pkd1l2) muscle. (J) Representative sections of gastrocnemius skeletal muscle from aged (.6 months) ostes/þ, Tg(Pkd1l2)/0 and ostes/þ,
Tg(Pkd1l2)/0 mice, stained with H&E. Ostes/þ skeletal muscle shows similar but much milder pathological hallmarks than ostes/ostes muscle, and no evidence
of overall muscle atrophy. Skeletal muscle from hemizygous Tg(Pkd1l2)/0 mice does not show any obvious myopathic changes or atrophy. However, skeletal
muscle from aged ostes/þ, Tg(Pkd1l2)/0 mice shows marked fibre size asymmetry, very small fibres and centrally nucleated regenerating fibres. Scale bar: 20,
100 mm, 40, 50mm. Inset: H&E-stained cross-sections of whole hind limbs from the same mice show no significant differences in size.
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To assess whether this polyinnervation was due to a delay in
developmental synapse elimination at the neuromuscular junc-
tion (NMJ), we examined motor endplates in 9-month-old
ostes/ostes mice (Fig. 1F). Polyinnervated endplates were
also observed in these mice, suggesting that this phenotype
was persistent and not due to prolongation of the period
over which synapse elimination would normally occur (1–2
weeks postnatal). Ostes/þ mice also showed evidence of poly-
innervation, but at lesser incidence than ostes/ostes mice, and
polyinnervation was not unequivocally found to be functional
(n ¼ 2 mice, data not shown). In both young and old ostes/
ostes and ostes/þ mice, normal mononeuronal innervation
of endplates was also observed (Fig. 1F). Therefore, three dis-
tinctive types of endplates were characteristically observed in
lumbrical muscles from ostes/ostes mice: monoinnervated
(50%, n ¼ 3), denervated (10%, n ¼ 3) and polyinner-
vated (40%, n ¼ 3).
The specific effects of the morphological changes in ostes/
ostes muscle on muscle function were also established. We
found that the hind limb muscles of ostes/ostes mice were
weaker than the corresponding muscles in age-matched
wild-type controls. Whereas tibialis anterior (TA) muscles in
wild-type mice produced a maximum tetanic force of 137g
(+5.3 SEM, n ¼ 6), this was reduced to only 32g (+2.1
SEM, n ¼ 10) in ostes/ostes mice (Fig. 2A). Similarly, the
maximum force in EDL muscles of wild-type mice was 25g
(+3.1 SEM, n ¼ 8) compared with only 13g (+0.8 SEM,
n ¼ 7) in ostes/ostes mice (Fig. 2A). The contractile character-
istics of these muscles in ostes/ostes mice were also assessed.
Although the time to peak force and the time taken to reach
half relaxation force were the same in TA and EDL muscles
of ostes/ostes and wild-type mice (Fig. 2B), there was a sig-
nificant change in the fatigue characteristics of EDL muscles
in ostes/ostes mice (Fig. 2C). EDL is normally a fast muscle
that fatigues rapidly when repeatedly stimulated (Fig. 2C).
However, EDL in ostes/ostes mice has a higher fatigue
index than that of wild-type (Fig. 2C), indicating that it has
become more fatigue resistant than normal.
Despite the presence of some denervated NMJs, the loss of
muscle force and change in fatigue characteristics observed in
hind limb muscles of ostes/ostes mice were not due to a loss of
motor units. Physiological assessment of motor unit survival
showed that EDL muscles in wild-type and ostes/ostes mice
were innervated by an average of 38.8 (+1.17 SEM, n ¼ 6)
Figure 1. Continued.
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and 36.7 (+0.88 SEM, n ¼ 6) motor neurons, respectively
(Fig. 3A). This finding, indicating that there was no loss of
motor axons in ostes/ostes mice, was supported by morpho-
logical assessment of motor neuron survival (Fig. 3B). We
found no difference in the number of motor neurons present
in the lumbar spinal cord of ostes/ostes mice and wild-type lit-
termates (Fig. 3B). This was supported by the lack of muscle
paralysis in either ostes/þ or ostes/ostes mice at any age.
Additionally, cross-sections of sciatic nerve showed no evi-
dence of demyelination in ostes/ostes mice (n ¼ 3) (Fig. 3C).
The ostes mutation maps to a 0.78 Mb region on distal
chromosome 8
The ostes mutant was identified in a complex recessive mouse
mutagenesis screen that involved ENU treatment of a hybrid
(C3H/HeH  101/H) strain (6). To facilitate genetic and func-
tional analysis, the ostes line was crossed to wild-type BALB/
c mice for 20 generations to generate a congenic ostes line.
Genetic mapping on ostes/ostes progeny from these crosses
established linkage to distal chromosome 8 between
D8Mit213 and D8Mit13. Two further outcrosses, to the
C57BL/6J and FVB inbred strains, also independently con-
firmed significant linkage to the same region on chromosome
8 (data not shown). Since the FVB strain showed the
highest rate of polymorphism with the initial mutagenized
background, this strain was selected for high-resolution
mapping. We generated and genotyped approximately 500
intercross progeny including both affected (ostes/ostes) and
non-affected (þ/þ and ostes/þ) offspring to utilize all recom-
bination events. This analysis refined the non-recombinant
region to 772 kb, between D8Mit89 and the in-house marker
FM3 (see Materials and Methods). Pkd1l2, Gcsh, Bcmo1,
Dynlrb2 and five additional predicted genes lie within this
region, comprising 94 coding exons in total (Ensembl v49,
May 2008; Supplementary Material, Table S1). All exons
and splice acceptor/donor sites were amplified by PCR from
genomic ostes/ostes DNA and screened for mutation by
sequencing, but intriguingly, no mutation was revealed. To
confirm this finding, we used a commercial next-generation
sequencing approach (NGS) to sequence all exons in the inter-
val. As no mutation in coding sequence was identified, this
analysis confirmed our previous results (see Materials and
Methods). To screen for cDNA variants, cDNA of all candi-
date genes except Pkd1l2 was successfully amplified and
sequenced from primary cDNA libraries from wild-type and
ostes/ostes tissues. This analysis revealed no ostes-specific
splicing variants of these genes. Therefore, this raised the
possibility that the ostes mutation could lie in a regulatory
element and that misregulation of one of these genes, rather
Figure 2. Physiological assessment of ostesmuscle. (A) Muscle force in ostes/ostes tibialis anterior (TA) and extensor digitorum longus (EDL) muscles. Examples of
tension recordings of isometric contractions from wild-type (þ/þ) and ostes/ostes TA and EDL, showing twitch and tetanic contractions elicited by stimulating the
motor nerve to both muscles. Both TA and EDL from ostes/ostes mice show decreased force, compared with wild-type (TA: wild-type n ¼ 6, ostes/ostes n ¼ 10;
EDL: wild-type n ¼ 8, ostes/ostes n ¼ 7). Data shown as mean maximum tetanic force+SEM. Max tetanus, maximum tetanic force. (B) Contractile characteristics
of ostes/ostesTA and EDL muscles. Time to peak and time to half relaxation are not significantly different in wild-type and ostes/ostesmuscle (TA: wild-type n ¼ 6,
ostes/ostes n ¼ 10; EDL: wild-type n ¼ 8, ostes/ostes n ¼ 7). Data shown as mean time+SEM. (C) Fatigue profile of ostes/ostes EDL muscle. Ostes/ostes EDL
(n ¼ 6) shows increased resistance to fatigue relative to wild-type EDL (n ¼ 6). Data shown as mean fatigue index+SEM.
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than a coding mutation, could underlie the ostes phenotype.
Intriguingly, 30 sets of primers in a large number of combi-
nations failed to amplify overlapping segments of the large
Pkd1l2 cDNA from several tissues including the liver,
kidney and muscle; therefore, a complete sequence scan for
this particular cDNA was not achieved.
To evaluate expression, we performed microarray analysis
on adult ostes/ostes and wild-type hind limb skeletal muscle
using the RNG-MRC Mouse 25k array (MRC Harwell)
which contained all of the nine genes from the non-
recombinant region. No significant differences in the
expression of these genes between ostes/ostes and wild-type
samples were found (Supplementary Material, Fig. S5A;
data deposited at ArrayExpress, accession number
E-MEXP-1873). Pkd1l2 was the only gene in this region for
which analysis of splicing variants or differences in expression
could not be established despite its reported expression in skel-
etal muscle (7). This was not due to technical problems,
because detection of Pkd1l2 to levels amenable for analysis
failed in direct cDNA amplifications, Q-PCR (see what
follows) and microarray experiments, whereas cDNAs from
other genes in the non-recombinant region were efficiently
detected using the same techniques and templates. However,
we considered Pkd1l2 to be a good candidate on the basis of
Figure 3. Motor neuron survival in ostes. (A) Assessment of motor unit number in ostes/ostes EDL. Examples of stepwise increments in twitch force from wild-
type (þ/þ) and ostes/ostes EDL in response to gradual intensity increases of stimulation of the motor nerve to the EDL. Motor unit number in ostes/ostes EDL is
not significantly different to wild-type EDL (n ¼ 6 per genotype). Data shown as mean motor unit number+SEM. (B) Motor neuron survival in ostes/ostes
mice. Shown are representative 20 mm-thick transverse sections of spinal cord from wild-type and ostes/ostes mice. Motor neurons are stained with gallocyanin
(blue). Data shown as mean motor neuron counts+SEM. The number of gallocyanin-stained motor neurons present in the sciatic motor pool of the ventral horn
of each spinal cord was determined by counting every third serial section (n ¼ 60 sections per mouse; n ¼ 6 per genotype). (C) Representative cross-section of
proximal regions of sciatic nerve from 6-week-old wild-type (þ/þ) (n ¼ 3) and ostes/ostes mice (n ¼ 3) fixed with osmium tetroxide and stained with methylene
blue. No demyelination of ostes/ostes motor neurons as evidenced by reduced myelin-to-lumen staining or by ‘onion-bulb’ morphology is seen. Note that ostes/
ostes motor neurons are markedly smaller than wild-type, reflecting the overall small size of ostes/ostes mice. Scale bar: 25 mm.
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the association of the homologous PKD1 gene with disease
and the fact that all genes in the non-recombinant region
except Pkd1l2 had been effectively ruled out. Thus, for all
these other genes, no coding or splicing mutations and no sig-
nificant expression differences between the mutant and control
were found. Therefore, we decided to assess expression of
Pkd1l2 in ostes/ostes mice at the protein level.
PKD1L2 protein is upregulated in ostes mice
We assessed Pkd1l2 as a candidate gene for ostes by generating
PKD1L2-specific antibodies and examining PKD1L2 protein
in ostes/ostes muscle. Two rabbit polyclonal antibodies,
APKD1L2_1 and APKD1L2_2, were generated and thoroughly
characterized (Fig. 4). Western blot analysis of soluble skeletal
muscle extracts from wild-type mice showed that both antibodies
recognized a band migrating at 268 kDa (Fig. 4B), consistent
with the PKD1L2 expected size (272 kDa). Western blot analysis
of multiple tissues showed that this band was the largest protein
recognized in several tissues (Supplementary Material,
Fig. S6A), suggesting that this protein is likely to be full-length
PKD1L2. We used immunoprecipitation to confirm the speci-
ficity of these antibodies. Antibody APKD1L2_1 specifically
and efficiently immunoprecipitated a protein migrating at
268 kDa from wild-type skeletal muscle lysates (Fig. 4C).
Analysis of the corresponding band by peptide mass fingerprint-
ing identified PKD1L2 among other proteins (see below
and Fig. 4C). In addition, the immunoprecipitated protein
was also recognized by the second antibody, APKD1L2_2
(Fig. 4C). We then assessed PKD1L2 protein expression in
ostes/ostes skeletal muscle. Since PKD1L2 is a predicted
transmembrane protein, PKD1L2 expression was assessed in
both soluble and membrane fractions. The results showed
that PKD1L2 is strongly accumulated in ostes/ostes skeletal
muscle compared with wild-type (n ¼ 8, representative
samples shown in Fig. 5). Accumulation was observed in both
Figure 4. Analysis of PKD1L2 protein in skeletal muscle. (A) Domain composition of PKD1L2 with the annotated position of peptides used to raise antibodies
APKD1L2_1 and APKD1L2_2. Functional domains as predicted by SMART (http://smart.embl-heidelberg.de/). C-LECT, C-type lectin (CTL) or
carbohydrate-recognition domain (CRD); Pfam Gal_Lectin, galactose-binding lectin domain; PKD, PKD domain; GPS, G-protein-coupled receptor proteolytic
site domain; LH2, lipoxygenase homology 2 (beta barrel) domain; blue rectangles, transmembrane domains; pink dots, low-complexity region. (B) Western blot
analysis using PKD1L2 antibodies. Both antibodies APKD1L2_1 and APKD1L2_2 recognize a 268 kDa protein in wild-type soluble skeletal muscle extracts.
APKD1L2_2 recognizes other bands of smaller size. WB, antibody used for western blot. (C) Immunoprecipitation and peptide analysis using APKD1L2_1
antibody on wild-type skeletal muscle extract. APKD1L2_1 specifically immunoprecipitates a 268 kDa band (left panel) that is also recognized by
APKD1L2_2 (middle panel). The right panel shows a Coomassie-stained gel in which the immunoprecipitated protein complex has been resolved. Proteins ident-
ified by mass spectrometry are indicated. IP, immunoprecipitation; WB, western blot; Lys, lysate; IPþ, immunoprecipitated sample; IP2, negative control.
(D) Reciprocal co-immunoprecipitation of PKD1L2 and FASN in skeletal muscle. Western blot analysis using AFASN antibody specifically recognizes a
268 kDa band from protein complexes immunoprecipitated using APKD1L2_1 antibody in skeletal muscle soluble fraction, from both wild-type and ostes/
ostes mice. Western blot analysis using APKD1L2 antibody specifically recognizes a 268 kDa band from protein complexes immunoprecipitated using
AFASN antibody in skeletal muscle soluble fraction, from both wild-type and ostes/ostes mice. PKD1L2 and FASN co-immunoprecipitation was also observed
in membrane fractions (bottom panels). IP, immunoprecipitation; WB, western blot; Lys, lysate; IPþ, immunoprecipitated sample; IP2, negative control.
Human Molecular Genetics, 2009, Vol. 18, No. 19 3559







soluble and membrane fractions (Fig. 5). These results
suggested that the upregulation of PKD1L2 underlies the
ostes phenotype.
In search of a putative regulatory mutation within the vicin-
ity of the Pkd1l2 gene that would explain the upregulation
of this gene in mutant mice, we used NGS to sequence
unique non-coding sequences in a 250 kb genomic segment
encompassing Pkd1l2 and flanking genes Bcmo1 and Gcsh,
that is, all genomic DNA except repetitive elements in that
interval. This analysis produced 149 kb of sequence from
ostes/ostes DNA, but no change was revealed, suggesting
that a regulatory mutation could exist in a non-conserved regu-
latory element somewhere else within the non-recombinant
interval.
Transgenic overexpression of PKD1L2 causes ostes-like
myopathic and innervation changes
We tested the hypothesis that the overexpression of PKD1L2
found in ostes/ostes mice causes neuromuscular dysfunction
in these mice by generating a transgenic mouse overexpressing
PKD1L2. Since a full-length Pkd1l2 cDNA could not be
amplified (discussed earlier), we opted to use a bacterial arti-
ficial chromosome (BAC) to generate a transgenic line. A
BAC (RP23-269J16) was selected which contained the full-
length genomic sequence of Pkd1l2 and the small flanking
genes Bcmo1 and Gcsh. These flanking sequences were
required to include the promoter and other possible regulatory
elements in the vicinity of the Pkd1l2 gene. Following micro-
injection of the BAC into fertilized oocytes, a transgenic
founder was identified (Tg(Pkd1l2)_#1). Subsequent crosses
showed that the BAC was transmitted to 57.5% (57 of 99)
of offspring from this mouse, thus indicating a single inte-
gration site. We examined hemizygous Tg(Pkd1l2)/0 mice
for evidence of neuromuscular dysfunction. Tg(Pkd1l2)/0
mice were indistinguishable from wild-type littermates and
did not show any overt phenotype, and histological analysis
did not reveal any anomalies on H&E-stained hind limb skel-
etal muscle sections (Fig. 1J). However, on intercrossing
Tg(Pkd1l2)/0 mice, we found that homozygous Tg(Pkd1l2)/
Tg(Pkd1l2) mice showed extreme growth retardation and
developed progressive hind limb dragging and paralysis
between 4 and 6 weeks of age. Nineteen per cent of intercross
offspring displayed this phenotype (13/64), and 3% were
found dead around this age (2/64), indicating that some post-
natal loss may be occurring. H&E-stained skeletal muscle sec-
tions from these mice showed extreme fibre size asymmetry,
pyknotic nuclei, small centrally nucleated fibres and no evi-
dence of macrophage infiltration, strongly recapitulating the
pathological hallmarks seen in ostes/ostes mice (Fig. 1C, D
and E and Supplementary Material, Figs S1 and S2). Similar
pathology was seen in pharyngeal muscle and diaphragm,
but not in any other 23 tissues analysed including the heart
(not shown). Moreover, fibre type analysis revealed a similar
distribution of fast and slow fibres to ostes/ostes muscle,
again showing a lack of both fibre-specific hypertrophy and
clustering (Fig. 1I and Supplementary Material, Fig. S4).
However, both ostes and Tg(Pkd1l2) homozygotes showed a
small but statistically significant reduction of type-2 fibre
size in soleus muscle (Fig. 1D). Additionally, polyinnervated
and denervated endplates were also evident in homozygous
Tg(Pkd1l2)/Tg(Pkd1l2) mice (n ¼ 4, representative examples
shown in Fig. 1H).
Given the similarities between the ostes and Tg(Pkd1l2)
myopathies, these results theoretically reduced the genetic
cause of the ostes disease to the upregulation of any of the
three genes in the BAC: Bcmo1, Pkd1l2 or Gcsh. We had
already established that PKD1L2 protein was elevated in
ostes mice. To unequivocally establish how expression
levels of these three candidate genes correlated with the
ostes neuromuscular disease, further expression analysis was
carried out. Real-time quantitative PCR was performed using
skeletal muscle from 10 ostes/ostes mice and 10 age- and sex-
matched wild-type controls. The results were consistent with
the microarray results described earlier: expression of Bcmo1
or Gcsh was not significantly different in ostes/ostes mice
(Supplementary Material, Fig. S5B), whereas Pkd1l2 was
not detected at sufficient levels for a reliable analysis. There-
fore, Bcmo1 and Gcsh have no coding or regulatory mutations
in ostes/ostes mice. Western blot analysis of skeletal muscle
from Tg(Pkd1l2)/Tg(Pkd1l2) mice showed that full-length
PKD1L2 was indeed overexpressed in this line (Fig. 5).
Further proof that the myopathies described in ostes and
Tg(Pkd1l2) homozygous mice share a common pathogenic
mechanism could be obtained from making double heterozy-
gotes. Thus, if ectopic expression of PKD1L2 as a result of
an ENU mutation or expression from a BAC clone was
respectively underlying myopathic changes in ostes/ostes and
Tg(Pkd1l2)/Tg(Pkd1l2) mice, we could expect double-
heterozygous mice (ostes/þ, Tg(Pkd1l2)/0) to show a more
severe pathology than the mild changes observed in ostes/þ
mice. In young mice, approximately 45 days old, the presence
of the BAC clearly exacerbated the mild myopathic changes of
ostes heterozygotes without adding any new distinctive feature
Figure 5. Western blot analysis of skeletal muscle extracts from wild-type, ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2) mice. (A) PKD1L2 and FASN show increased
levels in the membrane fraction of ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2) skeletal muscle. Samples shown are from individual mice (n ¼ 2 per genotype).
(B) PKD1L2 and FASN show increased levels in the soluble fraction of ostes/ostes skeletal muscle. Samples shown are from individual mice (n ¼ 2 per genotype).
PKD1L2 and FASN were detected, respectively, with antibodies APKD1L2_1 and mAFASN. þ/þ, wild-type; ost, ostes/ostes; Tg, Tg(Pkd1l2)/Tg(Pkd1l2).
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(Supplementary Material, Fig. S3). This result suggests that
increasing the copy number of the Pkd1l2 gene results in wor-
sening of the pathology caused by the ENU mutation. More-
over, ostes/þ, Tg(Pkd1l2)/0 mice (n ¼ 3) showed a
late-onset muscular atrophy and weakness of the hind limbs
between 6 and 10 months old, with foot-curling, unstable
gait and similar myopathic changes to those observed in
ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2) muscles (Fig. 1J).
These features were not found in aged ostes/þ (n ¼ 6) or
Tg(Pkd1l2)/0 mice (n ¼ 3) (Fig. 1J). These results indicated
that ostes and Tg(Pkd1l2) interact genetically and strongly
supported the hypothesis that the upregulation of PKD1L2
causes neuromuscular disease. These results did not strictly
exclude the possibility that a new mutation caused by the
insertion of the BAC and not the BAC itself was responsible
for the phenotype observed in the transgenic line. However,
the specificity of the pathological changes in the ENU-induced
and BAC-induced mutant lines and the genetic interaction
between the underlying genetic loci made that possibility
unlikely.
PKD1L2 interacts with fatty acid synthase in vivo
Our data showed that overexpression of PKD1L2 was associ-
ated with neuromuscular dysfunction in two mouse mutants.
However, neither PKD1L2 nor other TRPP channels have pre-
viously been shown to have roles in muscle. To explore a mol-
ecular role for PKD1L2 in muscle, we examined PKD1L2
protein complexes by immunoprecipitation from adult mouse
skeletal muscle lysates. Immunocomplexes precipitated with
antibody APKD1L2_1 were analysed by SDS–PAGE and
mass spectrometry to identify PKD1L2-interacting proteins.
Upon gel staining, a very prominent band was observed
migrating at 268 kDa, which was absent in the negative
control lane (Fig. 4C). A peptide mass fingerprint was gener-
ated from this band by mass spectrometry. Database search
using ProFound identified PKD1L2, as expected, but addition-
ally the enzyme fatty acid synthase (FASN) was identified as
the top scorer. FASN was also identified from bands of
smaller molecular weight, probably reflecting partial degra-
dation (Fig. 4C). The identity of this protein was confirmed
by western blot with a monoclonal antibody against FASN
(mAFASN) following immunoprecipitation with APKD1L2_1
antibody, from both wild-type and ostes/ostes skeletal muscle
soluble fractions (Fig. 4D). To further confirm the association
between PKD1L2 and FASN, we carried out immunoprecipita-
tion using mAFASN on wild-type and ostes/ostes skeletal
muscle soluble fractions. FASN was efficiently immunoprecipi-
tated, and subsequent western blot analysis confirmed that
PKD1L2 was present in the immunoprecipitated complex.
The same results were obtained using wild-type skeletal
muscle membrane fraction (Fig. 4D). Since the molecular
weight of FASN is equivalent to that of PKD1L2 (272 kDa),
and the two proteins co-migrate, this analysis did not exclude
the possibility that the APKD1L2_1 antibody might be cross-
reacting with FASN protein. To test for such cross-reactivity,
we examined PKD1L2 and FASN protein expression in differ-
ent mouse tissues. This analysis demonstrated that whereas
FASN was strongly expressed in every tissue examined,
expression of PKD1L2 was more restricted, thus indicating
that the APKD1L2_1 antibody does not recognize FASN
(Supplementary Material, Fig. S6A). Analysis of the same
samples using non-denaturing conditions produced a different
pattern for both antibodies on western blots (data not shown),
suggesting that PKD1L2_1 antibodies did not cross-react
against the FASN native form either. Moreover, affinity-
purified antibody APKD1L2_2, raised against a different
PKD1L2 epitope, also immunoprecipitated FASN (Sup-
plementary Material, Fig. S6B), and the reciprocal immuno-
precipitation using mAFASN antibody also produced a
268 kDa protein recognized by antibody APKD1L2_2, con-
firming the co-immunoprecipitation of FASN and PKD1L2
(Supplementary Material, Fig. S6B).
Despite PKD1L2 being a predicted transmembrane protein
and FASN a soluble cytoplasmic enzyme, their association
as revealed by immunoprecipitation of endogenous proteins
suggested that these proteins must have overlapping subcellu-
lar localizations. To assess this, immunostainings on cross-
and longitudinal sections of fresh-frozen skeletal muscle
samples were performed with APKD1L2_1 and a goat poly-
clonal antibody against FASN (gAFASN). PKD1L2 and
FASN were found localized to the membrane on cross-
sections (Fig. 6A). On longitudinal sections, both antibodies
produced overlapping localizations at striations overlying the
Z-discs on the surface of the fibre (Fig. 6A, middle panel)
but not at the centre (Fig. 6A, bottom panel). A similar
result was obtained with mAFASN antibody (Supplementary
Material, Fig. S7), suggesting a costameric localization of
both proteins. Costameric distribution was supported by
co-localization of PKD1L2 with the costameric transmem-
brane protein b-dystroglycan (8) on serial views of longitudi-
nal sections (Fig. 6C). An identical pattern was observed with
antibody APKD1L2_2, and for both PKD1L2 antibodies, the
fluorescent signal was effectively blocked upon pre-incubation
with their respective antigenic peptides (data not shown). On
the other hand, expression of PKD1L2 was also detected at
slightly higher levels at the postsynaptic membrane of the
NMJs (Fig. 7A and B).
FASN is overexpressed in ostes mice
We speculated that the overexpression of PKD1L2 in ostes/
ostes skeletal muscle could affect the expression or activity
of FASN in this tissue. Surprisingly, we found that FASN
was overexpressed in ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2)
skeletal muscle by western blot analysis, mirroring the overex-
pression of PKD1L2 (n ¼ 12, representative samples shown in
Fig. 5). Overexpression of FASN was observed in both soluble
and membrane fractions (Fig. 5) and was also confirmed to
occur at the transcriptional level (Supplementary Material,
Fig. S8A). The growth defect exhibited by the ostes mouse
is counterintuitive to an overexpression of FASN, as the
latter is generally found in conditions of metabolic overload
such as obesity (reviewed in 9). We therefore hypothesized
that PKD1L2 acts as a negative regulator of FASN and that
the upregulation of PKD1L2 in the ENU and transgenic
lines results in decreased FASN activity. In this hypothesis,
the increased expression of FASN in skeletal muscle of
ostes mice would result from a positive feedback regulatory
mechanism. Relative activity of FASN to total amount of
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FASN protein was measured in soluble fractions of ostes/ostes
and wild-type muscle by spectrophotometric analysis of
NADPH. NADPþ oxidation. Although there is a clear trend
showing reduced relative activity in ostes/ostes mice, FASN
activity varied widely in individual samples of the same gen-
otype, making the difference between ostes/ostes and control
statistically not significant (P ¼ 0.236) (Supplementary
Material, Fig. S8B). Therefore, we looked for other biochemi-
cal markers of lipid metabolism to determine whether fatty
acid biosynthesis was abnormal in ostes/ostes mice. We
assessed the blood plasma lipid profile of ostes/ostes mice
(Fig. 8A). Both triglyceride (TG) and free fatty acid (FFA)
levels were significantly and markedly decreased in plasma
from both male and female ostes/ostes mice, compared with
Figure 6. Co-localization of PKD1L2 and FASN in skeletal muscle. (A) Confocal microscopic analysis of fresh-frozen skeletal muscle sections from wild-type
mice immunostained with APKD1L2_1 and gAFASN antibodies. Top panel, a cross-section of muscle showing PKD1L2 and FASN co-localization at the mem-
brane. Middle panel: a view of the surface of longitudinally sectioned fibres showing PKD1L2 and FASN with overlapping localizations to striations. Bottom
panel: a deeper level of the same fibres showing PKD1L2 and FASN with overlapping localizations at the membrane. (B) For comparison, a view of the mid-
level of a longitudinal fibre stained with dystrophin and a-actinin using the same conditions. Note that, in contrast to the bottom panel shown in (A), the Z-discs
are stained here. (C) Top panel: superficial (‘Top’) and middle views of longitudinal fibres showing PKD1L2 co-localization with the costameric protein
b-dystroglycan. Bottom panel: a close-up view of top and middle levels of a single fibre. Scale bar: 25 mm.
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wild-types (Fig. 8A). Furthermore, total body fat content of
ostes/ostes mice was analysed by dual-energy X-ray absorptio-
metry (DEXA) analysis (Fig. 8B). The total fat percentage of
body mass was significantly decreased in ostes/ostes mice
from a mean wild-type percentage of 20 to 17% in
female ostes/ostes mice and from 17 to 14% in male
ostes/ostes mice (Fig. 8B). These results indicated a reduction
of lipogenesis in ostes mice.
DISCUSSION
In this work, we have characterized the neuromuscular pheno-
type of ostes mice and explored the underlying molecular
mechanism. Indeed, the genetic mechanism leading to the
upregulation of the linked Pkd1l2 gene in ostes mice
remains elusive despite meticulous sequencing efforts.
However, as indicated by the total protein levels, Pkd1l2 is
Figure 6. Continued.
Figure 7. PKD1L2 localizes to NMJs. (A) A longitudinal section showing the NMJ stained with bungarotoxin and overlapping localization with PKD1L2 (using
APKD1L2_2 antibodies). Note that PKD1L2 is slightly increased at the postsynaptic membrane. (B) NMJs identified on cross-section with antibodies against
utrophin. Note that PKD1L2 is slightly increased at the NMJs.
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the only gene in the non-recombinant region that is upregu-
lated in ostes/ostes mice, and there are identical pathological
findings in ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2) mice.
Common histological hallmarks include muscle fibre asymme-
try, scattered regenerating fibres, a lack of fibre type grouping,
whole-muscle atrophy and an irregular innervation pattern.
Conversely, typical dystrophic changes such as excessive con-
nective tissue or macrophage infiltration are not present in
either mutant. Disease manifestation is more severe in
Tg(Pkd1l2)/Tg(Pkd1l2) probably because the BAC transgene
does not exactly replicate the changes in Pkd1l2 gene
expression caused by the ostes ENU mutation. Intriguingly,
neither ostes/þ nor Tg(Pkd1l2)/0 mice showed any overt phe-
notype at young or old age (.9 months), but the double het-
erozygote suffered from a more severe myopathy that resulted
in late-onset gait defects. Hind limb muscle histology of the
latter showed changes qualitatively similar to those found in
young ostes/ostes mice and much more profound than those
of age-matched single heterozygotes. Altogether, these
results suggested that overexpression of Pkd1l2, which was
demonstrated at the protein level in both mutants, provokes
neuromuscular disease in mice. Pathological changes were
not found in any other tissue, including sciatic nerve and
spinal cord, suggesting that skeletal muscle is the primary
target tissue of this disease. The polyinnervation defects
found in ostes mice could thus be secondary to the myopathic
changes, but since PKD1L2 accumulates at NMJs on the post-
synaptic membrane, a role for this protein in regulating the
stability of NMJs is possible and merits further investigation.
PKD1L2 belongs to the TRPP family of proteins. The tran-
sient receptor potential (TRP) superfamily comprises a large
group of cation channel proteins usually containing six trans-
membrane domains, which, despite having diverse functions
and expression, appear to function as critical sensors of
environmental stimuli, at both organism and cellular levels
(reviewed in (10 and 11). The TRPP family includes two
genes that are associated with human disease: mutation of
TRPP1/PKD1 or TRPP2/PKD2 cause polycystic kidney
disease in humans (12,13) and mice (14,15). Other TRPP1-like
genes have been shown to have roles in taste reception (Pkd1l3
(16,17)) and reproductive success (Pkdrej (18)). Thus far, no
TRPP genes have been associated with neuromuscular func-
tion or disease. PKD1L2 is a large, complex protein of
unknown function. It is predicted to act as an ion channel
(7) and has also been reported to bind in vitro to two G-
proteins (19). The presence of FASN as the major component
of the PKD1L2-immunoprecipitated complex in skeletal
muscle suggests a functional relationship between these pro-
teins in this tissue. In mammals, FASN synthesizes de novo
long-chain, saturated fatty acids from malonyl-CoA and
acetyl-CoA, and is therefore a critical enzyme in lipogenesis
(20). In muscle, both imported and de novo-synthesized fatty
acids are used as an energy source via beta oxidation. The
increased levels of FASN protein in the skeletal muscle of
ostes mice are due to the upregulation at the transcriptional
level. This is not a non-specific response of skeletal muscle
to a disease condition because the actively regenerating
muscles of the muscular dystrophy ky mutant (21) do not
show FASN upregulation (Supplementary Material, Fig. S9).
However, the finding that FASN is overexpressed in ostes/
ostes mice is intriguing because ostes/ostes mice are small
and lean. Intriguingly, the dramatic accumulation of FASN
in ostes/ostes skeletal muscle did not result in an increase of
FASN activity. In fact, blood measurements of TGs and
FFAs as well as total fat deposition would suggest that lipid
metabolism is indeed compromised in the ostes homozygote.
Given that muscle has a particularly high metabolic need for
fatty acids driven by its high-energy demand, a reduction in
FASN activity would predictably compromise muscle func-
tion. Mice homozygous for a null allele of FASN show
embryonic lethality (22), but skeletal muscle was not exam-
ined in surviving Fasn heterozygous mice. A direct involve-
ment of FASN activity in muscle disease or indeed the
pathogenic mechanism of ostes cannot be tested at the
Figure 8. Lipid metabolism in ostes mice. (A) Lipid profiling in ostes/ostes mice. Blood lipids were analysed from fasted ostes/ostes (n ¼ 9 female, 11 male) and
wild-type (n ¼ 12 female, 12 male) mice for triglyceride (TG) and free fatty acid (FFA). Both male and female ostes/ostes mice showed significantly decreased
levels of both TG and FFA (TG: female: P ¼ 3.107E2 05; male: P ¼ 0.0001; FFA: female: P ¼ 0.0005; male: P ¼ 2.221E2 06). Data represented are mean
blood plasma levels+SEM. (B) Total percentage body fat in ostes/ostes mice. Total body fat was analysed by DEXA analysis in ostes/ostes (n ¼ 9 female, 11
male) and wild-type (n ¼ 22 female, 22 male) mice. Total percentage body fat was significantly decreased in both female and male ostes/ostes mice, compared
with wild-type (female: P ¼ 1.922E2 03, male: P ¼ 5.023E2 06). Data represented are mean percentage body fat+SEM.
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present time, as a Fasn skeletal-muscle conditional knockout
mouse has not been reported. However, a rare case of de
novo fatty acid synthesis deficiency resulting in persistent
myopathy and poor growth has been reported in humans.
This defect was due to the deficiency of the acetyl-CoA car-
boxylase enzyme, which catalyses the formation of the
FASN substrate malonyl-CoA (23), indicating that insufficient
fatty acid synthesis can cause pathological changes in skeletal
muscle. Moreover, the microarray data generated in this work
identified lipid metabolism as the major biological pathway
altered in ostes/ostes skeletal muscle: eight out of the top
nine genes upregulated in ostes/ostes muscle have functions
in lipid metabolism (Supplementary Material, Table S2; see
also deposited data ArrayExpress, accession number
E-MEXP-1873). Therefore, lipogenesis is altered at skeletal
muscle and systemic levels in ostes/ostes mice. The precise
reasons for the tissue specificity of this disease remain to be
established. Concomitant upregulation of FASN and
PKD1L2 was also detected in the kidney, but here the increase
in FASN is smaller than that observed in muscle; overexpres-
sion of both PKD1L2 and FASN was not detected in other
tissues from ostes/ostes mice, including the brain, spinal
cord and liver (Supplementary Material, Fig. S10A). In con-
clusion, our data suggest that PKD1L2-induced dysregulation
of lipid metabolism is a cause of complex neuromuscular
defects in mice. On that basis, we propose that PKD1L2 and
defective fatty acid synthesis should be assessed, respectively,
as a genetic risk factor and as a precipitating cause of neuro-
muscular disorders in humans.
MATERIALS AND METHODS
Additional methods are detailed in Supplementary Material.
Antibodies
Polyclonal antibodies to mouse PKD1L2 were generated in
rabbit using two PKD1L2 peptides (APKD1L2_1:
LVASTKVRPEDQRRQEATRA; APKD1L2_2: GNSKLV
GSAHIRQVRVRE) and independently affinity-purified
(NeoMPS Inc., San Diego, CA, USA).
Genetic mapping
The in-house-generated marker used was a microsatellite
marker FM3 (forward primer: 50-TCTGGGTTGGATGGA-
CATTT-30; reverse primer: 50-CCCAGATGATGGAAGGA
GAA-30). The ostes locus was genotyped on an FVB genetic
background using D8Mit89 and D8Mit120 (MGI), and
rs37591588 (NCBI).
BAC transgenesis
A BAC (identifier RP23-269J16) containing full-length
genomic sequence of Pkd1l2 was obtained from BACPAC
Resource Center, Children’s Hospital Oakland Research Insti-
tute (CHORI), Oakland, CA 94609, USA. DNA was prepared
from culture using the QIAGEN Large-Construct Kit, diluted
to 1 ng/ml and microinjected into fertilized FVB oocytes.
Resulting mice were screened for BAC integration by PCR
with primers designed against the vector: forward 50-ataaat
ggatgccctgcgta-30; reverse 50-ttcaacccagtcagctcctt-30. One
positive founder for the BAC was identified and bred to the
FVB strain to generate a colony. The line was submitted to
the Mouse Genomic Nomenclature Committee (The Jackson
Laboratory) and designated the identifier Tg(Pkd1l2)1Blac
(accession number MGI:3811813). For brevity, we refer to
this line in this publication by the shortened identifier
Tg(Pkd1l2).
FASN activity assay and HeLa cell culture
FASN-specific activity in soluble fraction of skeletal muscle
from 3-month-old female wild-type (n ¼ 4) and ostes/ostes
(n ¼ 4) mice was measured as described in Nepokroeff et al.
(24), except that mice were fed ad libitum before sacrificing.
Untreated, and serum-deprived and insulin-treated, HeLa
cells were used as positive control. HeLa cell culture, treat-
ment and protein isolation were performed as described in
Alberts et al. (25). FASN protein amounts were quantified
by densitometric analysis using QuantityOne software
(Bio-Rad) from western blot of equally loaded cytosolic frac-
tions and were normalized to GAPDH. FASN relative activity
was calculated using the following formula: FASN activity ¼
FASN-specific activity (units/mg/min)/FASN total protein
(arbitrary units). Statistical testing was performed using a two-
tailed Student’s t-test.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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